Periostin peptide-treated animals were marked by a 27% reduction in infarct scar volumes when compared to control animals by 12 weeks post administration, while there was no difference between groups 2 days after MI creation (Fig. 5b). This evidence concerns the gene POSTN and myocardial infarction.